Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J scores $1.2 bil. in stent patent fight

This article was originally published in The Gray Sheet

Executive Summary

Appeal of a $1.2 billion stent patent infringement judgment in favor of Johnson & Johnson/Cordis is the next step for defendants Boston Scientific and Medtronic. Final judgment entered in Delaware federal court Sept. 30 calls for Boston Scientific to pay $703 million in damages and pre-judgment interest, and Medtronic to pay $521 million. The award follows jury findings in 2000 and 2005 that the firms infringed J&J's Palmaz patent. An Oct. 1 report from Morgan Stanley analyst David Lewis suggests that the legal ruling, while "not insignificant," is "manageable" for Boston Scientific and Medtronic, in part since both firms have already established some reserves to help pay the costs and they will look to appeal. The companies no longer offer stents using the infringing platforms (1"The Gray Sheet" Sept. 22, 2008, In Brief)

Related Content

Boston Scientific Settles 14 Stent Patent Suits With J&J For $716 Million
Coronary stent patent case resolution (again)



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts